Sinsin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Sinsin Pharmaceutical has a total shareholder equity of ₩62.1B and total debt of ₩44.4B, which brings its debt-to-equity ratio to 71.5%. Its total assets and total liabilities are ₩124.4B and ₩62.3B respectively. Sinsin Pharmaceutical's EBIT is ₩6.0B making its interest coverage ratio 3.2. It has cash and short-term investments of ₩346.5M.
Key information
71.5%
Debt to equity ratio
₩44.37b
Debt
Interest coverage ratio | 3.2x |
Cash | ₩346.46m |
Equity | ₩62.09b |
Total liabilities | ₩62.32b |
Total assets | ₩124.41b |
Recent financial health updates
Recent updates
Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues
Mar 20What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?
Mar 06Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?
Feb 08If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today
Jan 18We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability
Dec 25What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?
Nov 29Financial Position Analysis
Short Term Liabilities: A002800's short term assets (₩47.1B) do not cover its short term liabilities (₩51.7B).
Long Term Liabilities: A002800's short term assets (₩47.1B) exceed its long term liabilities (₩10.6B).
Debt to Equity History and Analysis
Debt Level: A002800's net debt to equity ratio (70.9%) is considered high.
Reducing Debt: A002800's debt to equity ratio has increased from 52.3% to 71.5% over the past 5 years.
Debt Coverage: A002800's debt is not well covered by operating cash flow (8.9%).
Interest Coverage: A002800's interest payments on its debt are well covered by EBIT (3.2x coverage).